



(51) International Patent Classification:

A61K 31/4045 (2006.01) A61P 29/00 (2006.01)
 A61K 31/5375 (2006.01) A61P 31/00 (2006.01)
 C07D 209/20 (2006.01) A61P 25/00 (2006.01)
 C07D 295/104 (2006.01) C07F 5/04 (2006.01)
 A61P 37/00 (2006.01) C07K 5/065 (2006.01)
 A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2011/026629

(22) International Filing Date:

1 March 2011 (01.03.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/309,366 1 March 2010 (01.03.2010) US

(71) Applicant (for all designated States except US): **ONYX THERAPEUTICS, INC.** [US/US]; 2100 Powell Street, Emeryville, California 94608 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SHENK, Kevin D.** [US/US]; 565 Arastradero Road, #203, Palo Alto, California 94306 (US). **PARLATI, Francesco** [US/US]; 1035 York Street, San Francisco, California 94110 (US). **BENNETT, Mark K.** [US/US]; 9 Fieldbrook Place, Moraga, California 94556 (US).(74) Agent: **LAVOIE, Teresa, A.**; P. O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))


— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: COMPOUNDS FOR IMMUNOPROTEASOME INHIBITION



(I)

(57) Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.